Luye Pharma Group (HK:2186) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Luye Pharma Group has announced the inclusion of several innovative drugs, including Ruoxinlin and Baituowei, in China’s 2024 National Reimbursement Drug List. This development is expected to enhance patient access and accelerate commercialization, potentially boosting financial returns for the company. The inclusion marks a significant milestone for Luye’s proprietary antidepressant, Ruoxinlin, as a breakthrough ‘Made-in-China’ drug.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
